Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:44 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Half-Dose Intracoronary Abciximab Bolus Improves the Mortality Outcome Compared to Standard Intravenous Regimen
NCT00320229 · Azienda Sanitaria Ospedaliera · PHASE4 · terminated · last registry update 2006-05-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Azienda Sanitaria Ospedaliera |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ITGB3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2007-05-03Also stopped (terminated): University of Zurich, Abciximab (NCT00126139)
- 2007-05-03Also stopped (terminated): University of Zurich, Abciximab (NCT00167765)
- 2007-01-25Phase 3 first posted: GlaxoSmithKline, Abciximab + Eptifibatide (NCT00426751)
- 2006-03-06Phase 3 first posted: University of Leipzig, Abciximab i.v. + Abciximab i.c. (NCT00299377)
- 2006-01-02Phase 3 first posted: Centocor, Inc., Abxicimab + Heparin (NCT00271401)
- 2005-12-26Phase 3 first posted: Centocor, Inc., Abciximab + Placebo (NCT00269893)
- 2005-12-26Phase 3 first posted: Centocor, Inc., Abciximab + Placebo (NCT00269906)
- 2005-12-26Phase 3 first posted: Centocor, Inc., Placebo + Heparin (NCT00269880)
- 2005-11-10Phase 3 first posted: Organon and Co, A-Phase: tirofiban; Z-Phase simvastatin + Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years (NCT00251576)
- 2005-09-22Phase 3 first posted: Società Italiana di Cardiologia Invasiva, a drug against ITGB3 (NCT00220571)
- 2005-09-14Phase 3 first posted: University of Zurich, Abciximab (NCT00167765)
- 2005-09-12Phase 3 first posted: University Hospital Tuebingen, ReoPro (NCT00156611)
- 2005-08-02Phase 3 first posted: University of Zurich, Abciximab (NCT00126139)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision